Clinical trials: Multiple Primary Neoplasm
Hypercholesterolemia, Dyslipidemia
Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A
A Randomized, Double blind, Parallel, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A in Patient with primary Hypercholesterolemia or Mixed Dyslipidemia
- Trial name
- NCT05970679
- Testing
- Ezetimibe/Atorvastatin 10/5 mg, Atorvastatin 5mg, Ezetimibe 10mg
- Where
- South Korea
- Volunteers
- 252 people
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Diphtheria, Tetanus
Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants
The purpose of the study is to evaluate immunogenicity and safety of three different doses of candidate hexvalent vaccine in comparison to co-administration of EupentaTM Inj.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT04073459
- Testing
- DTwP-HepB-Sabin IPV-Hib, Pentavalent vaccine and Salk IPV
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- LG Chem
Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors
This is a Phase 1, open-label, two-part study designed to characterize the PK of an IV dose of approximately 12 µg tazemetostat that contains approximately 500 nCi of [14C] tazemetostat and the ADME of an oral dose of 800 mg…
- Conditions
- Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle-Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT03010982
- Testing
- Tazemetostat and [14C] Tazemetostat
- Where
- 2 sites in United Kingdom
- Volunteers
- 3 people
- Sponsor
- Epizyme, Inc.
Migraine
Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects
The primary purpose of this study is to evaluate the safety and tolerability of multiple oral doses of AMG 333 for 14 days in healthy subjects and migraine subjects.
- Trial name
- NCT02132429
- Testing
- AMG 333
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Amgen
Erectile Dysfunction
Evaluation of LEVITRA to Advance the Treatment of Erectile Dysfunction
This is a multicentre, cluster-randomized, open-label flexible dose study with a 2x2 factorial design with administration of vardenafil at a dose of 5, 10 and 20 mg doses in males with erectile dysfunction.The treatment period is…
- Trial name
- NCT00664833
- Testing
- Levitra (Vardenafil, BAY38-9456), No Education
- Volunteers
- 1,029 people
- Sponsor
- Bayer
Symptomatic Neurogenic Orthostatic Hypotension, Parkinson's Disease
A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy
Evaluate the clinical efficacy and safety of droxidopa versus placebo over a 17 week (maximum) treatment period in patients with symptomatic NOH.
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension, Parkinson's Disease, Multiple Systems Atrophy, Pure Autonomic Failure
- Trial name
- NCT01927055
- Testing
- Droxidopa
- Where
- 3 sites in United States
- Volunteers
- 61 people
- Sponsor
- Chelsea Therapeutics
Breast Cancer
Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy
This study is to measure the extent of tumor shrinkage when Letrozole and Zoledronic Acid are given before surgery to newly diagnosed post-menopausal women with early breast cancer
- Trial name
- NCT00247650
- Testing
- Zoledronic Acid; Letrozole
- Where
- 10 sites in Canada
- Volunteers
- 190 people
- Sponsor
- Novartis
Symptomatic Neurogenic Orthostatic Hypotension
Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
To evaluate the time to treatment intervention in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Non-Diabetic Autonomic Neuropathy (NDAN) or Dopamine Beta Hydroxylase (DBH)…
- Trial name
- RESTORE (NCT02586623)
- Testing
- Droxidopa capsules
- Where
- 168 sites in United States
- Volunteers
- 453 people
- Sponsor
- H. Lundbeck A/S
Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex
The purpose of this study is to investigate behavioral and other co-occurring outcomes with EPID(I/Y)OLEX as an add-on therapy in participants aged 1 to 65 years with tuberous sclerosis complex (TSC) who experience seizures.
- Trial name
- EpiCom (NCT05864846)
- Testing
- Cannabidiol Oral Solution [Epidiolex]
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 79 people
- Sponsor
- Jazz Pharmaceuticals
Hypercholesterolemia
A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)
The purpose of this study was to evaluate the long-term safety and tolerability of ezetimibe 10 mg once daily co-administered with atorvastatin 10 to 80 mg daily for up to 12 consecutive months in participants with heterozygous…
- Trial name
- NCT03882996
- Testing
- Ezetimibe, Atorvastatin
- Volunteers
- 432 people
- Sponsor
- Organon and Co
Sleep Initiation and Maintenance Disorders
Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus
The purpose of this study is to assess efficacy and safety of volinanserin in the population of patients complaining of sleep maintenance insomnia.
- Trial name
- SAMS (NCT00464061)
- Testing
- Volinanserin
- Where
- 22 sites in United States, Argentina and 20 more
- Volunteers
- 1,847 people
- Sponsor
- Sanofi
Epilepsy
Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures
Zonisamide is already marketed for the treatment of partial seizures in epilepsy. This study is intended to provide evidence that zonisamide is safe and effective in the treatment of primary generalised tonic-clonic seizures.
- Trial name
- NCT00692003
- Testing
- Zonisamide
- Where
- 73 sites in Australia, Croatia and 11 more
- Volunteers
- 21 people
- Sponsor
- Eisai Limited
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy
Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy…
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
- Trial name
- NOH302 (NCT00633880)
- Testing
- Droxidopa
- Where
- 54 sites in United States, Australia and 2 more
- Volunteers
- 181 people
- Sponsor
- Chelsea Therapeutics
Rheumatoid Arthritis, Osteoarthritis
A Multi-centre Study to Assess the Long-term Performance of the DePuy PROXIMA™ Hip in Primary Total Hip Replacement
The purpose of this study is to monitor the performance of the DePuy PROXIMA™ hip in the treatment of patients with hip joint disease requiring a total hip replacement.
- Conditions
- Rheumatoid Arthritis, Osteoarthritis, Post-traumatic Arthritis, Avascular Necrosis
- Trial name
- NCT00208455
- Testing
- DePuy Proxima™ Hip
- Where
- 4 sites in Germany, Italy and 2 more
- Volunteers
- 184 people
- Sponsor
- DePuy International
Myelofibrosis
Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.
This was an open-label, multi-center, randomized phase 2 study. This is a two-stage design.In the first stage, two dose groups were set up, the 100 mg bid dose group and the 200 mg qd dose group, which were randomized at 1:1…
- Trial name
- NCT03886415
- Testing
- Jaktinib hydrochloride tablets
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Hypercholesterolemia
The Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients with Primary Hypercholesterolemia
- Trial name
- NCT03288038
- Testing
- Rosuvastatin, Ezetimibe
- Where
- 20 sites in South Korea
- Volunteers
- 382 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Tuberous Sclerosis, Angiofibroma
Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)
The purpose of this trial is to evaluate the efficacy and safety of NPC-12G gel (topical formulation of sirolimus) versus placebo gel to facial angiofibroma and other skin lesions in patients with tuberous sclerosis complex (TSC)
- Conditions
- Tuberous Sclerosis, Angiofibroma, Hypomelanotic Macule, Plaque
- Trial name
- NCT02635789
- Testing
- NPC-12G gel
- Where
- Japan
- Volunteers
- 62 people
- Sponsor
- Nobelpharma
IgA Nephropathy (IgAN)
IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy
Part 1 is a Single Ascending Dose (SAD) study, and Part 2 is a Multiple Ascending Dose (MAD) study
- Trial name
- NCT07886476
- Testing
- IBI3034, Telitacicept
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Multiple Sclerosis
Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina
This observational study is being conducted to evaluate the usefulness of the MSFC and its relationship with EDSS scores in subjects with MS in Argentina.
- Trial name
- NCT01080014
- Where
- Argentina
- Volunteers
- 252 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety and effectiveness of EB103 in R/R B-cell NHL patients with the highest unmet medical needs, such as Human Immunodeficiency Virus (HIV)-associated…
- Conditions
- B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma
- Trial name
- STARLIGHT-1 (NCT06343311)
- Testing
- EB103
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- Estrella Immunopharma, Inc.